Daily Digest
Daily Digest
Company hub
Everything Pomegra has published on LLY: 25 news articles and 9 market briefs, newest first.
Eli Lilly (LLY) won China's first oral GLP-1 weight-loss pill nod, with sales up 39% last quarter.
1h ago
Novo Nordisk (NVO) shares hit 6.6% intraday as the Wegovy pill sold 5.4B kroner, beating forecasts.
Nov 4
The S&P 500 (SPX) closed at 7,580 as traders weighed a likely Democratic Congress for defense, drugs and AI
Nov 1
Eli Lilly (LLY) sales hit $24.4B, up 39%, while Merck (MRK) beat forecasts as Keytruda sales rose 6%.
Oct 29
Eli Lilly (LLY) jumped 4.7% to a record as the Dow closed near 52,514, the Nasdaq stayed flat and oil fell.
Oct 20
Eli Lilly (LLY), Merck (MRK) and AstraZeneca (AZN) beat a falling market as hot inflation hit tech stocks
Oct 14
The 100% tariff now hits drugmakers without pricing deals; Pfizer (PFE) and 16 peers are exempt to 2029.
Sep 30
Eli Lilly (LLY) spent $31B on 13 acquisitions in 2026, pushing global pharma M&A to a record $194B.
Sep 21
Amgen (AMGN) fell on pelacarsen's Phase 3 miss and a BMO Capital downgrade, pulling Eli Lilly down 2%.
Sep 11
Hims & Hers shares fell 8.7% after a third 2026 adjusted EBITDA cut, a surprise $33 million Q3 loss and a 100,000 drop in subscribers to 2.79 million.
Eli Lilly shares rose about 2% as Jefferies set a Street-high $1,700 target and oral obesity pill Foundayo posted positive Phase 3 sleep apnea data on Monday.
Novo Nordisk (NVO) shares rose about 6% premarket after a Q3 2026 earnings beat and a higher full-year outlook, driven by Wegovy pill and GLP-1 demand.
Eli Lilly's market value sits above $1 trillion on Zepbound and Mounjaro sales and a raised outlook, as Novo Nordisk reports Wednesday under obesity price pressure.
Eli Lilly (LLY) and Mastercard (MA) report before the open Thursday, with options pricing a 6.6% Lilly move on obesity-drug demand and spending in focus.
Eli Lilly (LLY) shares hit a record near $1,311 after Goldman raised its target to $1,413, a day after BofA, ahead of its Oct. 29 third-quarter report.
Biogen (BIIB) stock hit a 52-week high after JPMorgan upgraded it to Overweight with a $300 target, citing a run of late-stage trial readouts through 2027.
Ken Langone told CNBC that Eli Lilly (LLY) could reach $2,000 in three to four years, citing a $17-18B annual R&D budget and pipeline depth well beyond GLP-1s.
NVO shares slid as much as 9% after its Capital Markets Day in London, as a $23B pipeline target and patent-cliff questions hammered investor confidence in the Wegovy maker's growth story.
Artisan Partners is demanding a Novartis board overhaul and M&A strategy reset after three consecutive clinical failures erased roughly $30 billion in market value, with NVS stock staging a…
Novartis's pelacarsen fails its 8,323-patient Phase 3 cardiovascular trial despite Lp(a) lowering, sending Amgen 10% lower and clouding Lilly's competing pipeline.
Novartis's pelacarsen missed the primary endpoint in the 8,323-patient Lp(a)HORIZON trial Sept. 7, raising the unsettling question of whether lowering lipoprotein(a) prevents cardiovascular events…
LLY pays up to $1.88 billion for Merida Biosciences, gaining MER511, a Phase 1 biologic targeting autoantibodies in Graves' disease and thyroid eye disease.
Eli Lilly's retatrutide cleared Phase 3 with near-surgical weight loss as Orforglipron prescribers surged from 8,000 to 36,000 since launch, setting up a Q1 2027 BLA filing.
Eli Lilly's second-quarter earnings demolish expectations by $2.3 billion, fueled by record Mounjaro and Zepbound demand, sending LLY shares surging more than 6.5%.
Eli Lilly's up-to-$3.8 billion acquisition of clinical-stage AtaiBeckley marks the largest psychedelic medicine investment to date, targeting a fast-growing treatment-resistant depression market…
Q32 Bio stock jumped 83% on July 13 after Phase 2a data showed bempikibart cut hair-loss severity scores by 35% in patients with severe alopecia areata, including those who had failed JAK inhibitors.
Analysts flag chronic use as the structural thesis behind Eli Lilly's Foundayo, as next-generation retatrutide data and a $1 trillion market cap redefine the weight loss drug landscape.
Eli Lilly's Foundayo emerges as a lifetime obesity drug, backed by weight regain data and analyst forecasts of $14.8 billion in peak annual sales.
Germany's Chancellor insists Washington must abide by the existing US-EU trade agreement after the U.S. Trade Representative launches a Section 301 pharmaceutical probe targeting Berlin's drug…
Eli Lilly's acquisition of 4E Therapeutics adds a first-in-class MNK inhibitor pipeline targeting neuropathic and chronic pain without opioid-linked side effects.
Eli Lilly's acquisition of 4E Therapeutics bolsters its non-opioid chronic pain pipeline, adding a first-in-class MNK inhibitor with Phase 1 clinical data.
Eli Lilly taps NBA Hall of Famer Shaquille O'Neal to anchor its "Watch This" campaign for Zepbound — the first FDA-approved drug for moderate-to-severe obstructive sleep apnea in adults with obesity.
Eli Lilly and Ascidian Therapeutics ink a $1.9 billion RNA-editing collaboration targeting inherited kidney diseases, the latest deal in Lilly's accelerating genetic medicine expansion.
Eli Lilly's next-generation obesity drug retatrutide delivered average weight loss of 28.3% over 80 weeks in a pivotal Phase 3 trial — results that match outcomes typically associated with…
Pomegra